Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRx0237 in Mild to Moderate Alzheimer's Disease
NCT01689246Phase 3Completed
- Sponsor
- TauRx Therapeutics Ltd
- Start
- Jan 2013
- Primary completion
- Nov 2015
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial of hydromethylthionine mesylate in Alzheimer's disease (AD), sponsored by TauRx Therapeutics Ltd. Started Jan 2013; status: completed.
02
Drugs
hydromethylthionine mesylate
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01689246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01689246.